A Long-term, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Novel HPV Vaccine in Healthy Female Subjects Vaccinated in the Primary Study [EXTENSION of 700009996]
Latest Information Update: 06 Sep 2023
Price :
$35 *
At a glance
- Drugs GSK 568893A (Primary) ; AS04A; Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 04 Oct 2011 Actual end date of the extension trial (NCT00359619) is Aug 2009.
- 04 Oct 2011 Actual end date of the extension trial (NCT00359619) is Aug 2009.
- 04 Oct 2011 Actual end date of the extension trial (NCT00359619) is Aug 2009.